Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03090230 · ClinicalTrials.gov registry record · NA

Study of the Relay Pro® Thoracic Stent-Graft in Subjects With Traumatic Injury of the Descending Thoracic Aorta

A NA study of Other Specified Injury of Thoracic Aorta, sponsored by Bolton Medical.

Active
Registry status
NA
Development phase
50
Enrollment target
16
Study locations

NCT03090230 is a NA study of Other Specified Injury of Thoracic Aorta that is active but no longer recruiting, run by Bolton Medical. The registered enrollment target is 50 participants. The trial reports 16 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03090230, a NA study of Other Specified Injury of Thoracic Aorta, is active but no longer recruiting, sponsored by Bolton Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
16
Study locations

Study Summary

The purpose of this study is to investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with traumatic injury of the descending thoracic aorta (DTA)

Interventions

  • DEVICE Relay Pro Thoracic Stent-Graft System

Study Locations (16)

California

  • University of California, Irvine - Irvine
  • Stanford Medicine - Stanford

Connecticut

  • Yale School of Medicine - New Haven

Georgia

  • Grady Memorial Hospital - Atlanta

Indiana

  • Indiana University Health - Indianapolis

Iowa

  • University of Iowa Hospital and Clinic - Iowa City

Maryland

  • University of Maryland Medical Center - Baltimore

Massachusetts

  • Beth Israel Deaconess Medical Center / Harvard Medical School - Boston

Missouri

  • St. Louis University - St Louis

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2017-04-17
Est. Completion 2025-11-22
Phase NA

Sponsor

Bolton Medical

10 total trials

What the Registry Record Tells You About NCT03090230

The ClinicalTrials.gov registry entry for NCT03090230 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bolton Medical, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Other Specified Injury of Thoracic Aorta appearing as the primary indexed condition, and to 1 intervention - of which Relay Pro Thoracic Stent-Graft System is the first listed.

NCT03090230 reports 16 study locations spanning 15 distinct geographic areas - top geographies include California, Connecticut, Georgia.

Frequently Asked Questions

What is clinical trial NCT03090230 about?

NCT03090230 is a clinical study titled "Study of the Relay Pro® Thoracic Stent-Graft in Subjects With Traumatic Injury of the Descending Thoracic Aorta". The purpose of this study is to investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with traumatic injury of the descending thoracic aorta (DTA)

What is the current status of trial NCT03090230?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2017-04-17. Estimated completion is 2025-11-22.

What conditions does trial NCT03090230 study?

This clinical trial studies the following conditions: Other Specified Injury of Thoracic Aorta.

What interventions are being tested in trial NCT03090230?

The interventions under investigation include: Relay Pro Thoracic Stent-Graft System (DEVICE).

Who is sponsoring clinical trial NCT03090230?

This trial is sponsored by Bolton Medical, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03090230 being conducted?

This trial has 16 study locations across California, Connecticut, Georgia, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.